ArticleVirchows Archiv : an international journal of pathology2026
Pancreatic ductal adenocarcinomas arising from intraductal papillary mucinous neoplasms are aggressive despite being low stage: implications on screening and "early diagnosis".
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The literature is highly conflicting regarding the nature and behavior of pancreatic ductal adenocarcinomas (PDAC) arising from intraductal papillary mucinous neoplasm (IPMN). We investigated and contrasted the clinicopathological features of PDACs associated with IPMN (I-PDAC, n = 52 - only bona-fide and ≥ 1 cm IPMNs along with ordinary pancreatobiliary type invasive adenocarcinomas were included in this group-), versus without (NI-PDAC, n = 390) versus those associated with other IPMN mimicker cysts (pseudo-IPMN-associated, ps-PDAC, n = 39) including retention cysts. In I-PDAC, the average size of the IPMN was 4.05 cm, and 36.5% were > 3 cm, and the PDAC components were captured at an earlier stage (49% pT1) as compared to NI-PDACs (21% pT1), and ps-PDACs (18% pT1). I-PDAC also had a lesser frequency of lymphovascular invasion and lymph node metastasis. However, despite being less advanced PDACs, the overall survival of patients with I-PDACs was only modestly superior to NI-PDACs and ps-PDACs without statistical significance (median survival 44.2 vs. 26.7 vs. 28.4 months, and 5-year survival 41.4% vs. 24% and 0%), and this gap further closed when PDAC size was matched. This data underscores: (1) In > 60% of I-PDACs, the IPMN component is < 3 cm. (2) Contradictory to the prevailing impression in the literature, conventional PDACs arising from frank IPMNs do not behave that much better than ordinary PDACs despite being less advanced. (3) Even small PDACs may warrant adjuvant treatment. (4) Additional studies are needed to preoperatively distinguish "trivial cysts" from progression-prone IPMNs. 4) Following surgical resection of PDAC, it is still important to distinguish the nature of a cyst ≥ 1 cm as IPMN vs. pseudo-IPMN as ps-PDACs are significantly more aggressive which may be related to their ability to cause secondary cystic changes which requires further scrutiny. (5) Screening and removing IPMNs before they become invasive is crucial. 5) Even "early" may be too late: Even I-PDACs that are early stage are lethal which may necessitate re-focusing research efforts on biology, and etiopathogenesis such as anatomy associated chemical carcinogenetic factors.
Indexed as
Identifiers
42678419What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.